查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012666

輔助生殖技術市場：按產品、技術、週期類型、治療方法和最終用戶分類－2026-2032年全球市場預測

Assisted Reproductive Technology Market by Product, Technique, Cycle Type, Treatment, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，輔助生殖技術 (ART) 市場價值將達到 347.6 億美元，到 2026 年將成長至 409.4 億美元，到 2032 年將達到 1,115.1 億美元，年複合成長率為 18.11%。

主要市場統計數據
基準年 2025 347.6億美元
預計年份：2026年 409.4億美元
預測年份 2032 1115.1億美元
複合年成長率 (%) 18.11%

臨床、營運和商業性趨勢正在重塑輔助生殖技術服務和相關人員的優先事項，本文概述了這些趨勢的簡明策略框架。

輔助生殖技術正快速發展，迫使相關人員重新檢視關於臨床實務、商業模式和病人歷程的傳統觀念。新的診斷技術、不斷擴展的醫療服務網路以及患者期望的改變，正在重塑醫療服務的提供方式。因此，臨床、診斷、器材及相關服務領域的領導者需要對醫療、監管和商業性趨勢有全面的了解，才能做出及時、以證據為基礎的決策。

科學突破、營運整合和數位創新如何共同重塑輔助生殖技術的臨床路徑和商業模式。

輔助生殖技術領域正經歷著由科學創新、營運整合和以病人為中心的護理模式所驅動的變革。基因檢測和胚胎選擇技術的進步正在最佳化臨床路徑，減少治療週期的差異，並更加重視術前診斷。同時，檢查室自動化和冷凍保存技術的進步使診所能夠簡化處理流程，提高整體治療的可重複性。

評估近期關稅變化和貿易趨勢如何重塑整個輔助生殖技術供應鏈的採購、製造地和成本管理策略。

關稅政策的變化和國際貿易趨勢正對輔助生殖技術零件和設備的供應鏈產生累積影響。進口關稅會影響專用檢測設備、顯微鏡、培養箱和低溫儲存系統的到貨成本，而試劑和培養基的關稅則會影響診所和精密檢查室的日常運作成本。因此，採購慣例正轉向多元化的採購策略，並越來越重視與擁有強大物流能力的供應商建立夥伴關係。

透過多方面的細分，我們確定每種技術、週期類型、治療方法、最終用戶和產品類型的產品開發、臨床支援和商業性方法的優先事項。

基於細分市場的深入分析揭示了每項臨床技術、週期類型、治療方法、終端用戶環境和產品類型如何產生獨特的商業性需求和推廣障礙。諸如輸卵管內配子移植、體外受精 (IVF)、卵胞漿內單一精子注射 (ICSI)、子宮內人工授精 (IUI) 和胚胎移植 (EMF) 等技術，各自對資源、技術人員技能和檢查室基礎設施的要求各不相同。 IVF 尤其突出，其操作流程複雜，且涵蓋多種臨床路徑，包括新鮮供卵週期、新鮮非供卵週期和冷凍週期。就週期類型而言，新鮮供卵週期、新鮮非供卵週期和冷凍週期之間的差異會影響治療安排、冷凍保存需求和患者諮詢重點，促使診所製定差異化的操作手冊。

區域法規環境、臨床專業知識分佈和病患需求模式如何為美洲、歐洲、中東、非洲和亞太地區創造不同的機會。

區域趨勢對輔助生殖技術的臨床實務模式、投資意圖和監管趨勢有顯著影響。在美洲，公私醫療資金的混合投入推動了診所網路的競爭、強勁的患者需求以及創業投資帶來的積極創新，而專業檢測能力則集中在都市區。在歐洲、中東和非洲（EMEA），不同的管理體制和報銷框架影響先進診斷技術和檢查室自動化技術的市場准入和普及。跨境合作和醫療旅遊也影響專業服務的提供地點。亞太地區的特點是設備快速擴張、臨床專業水平不斷提高以及監管成熟度不一，這為能夠適應當地臨床工作流程和價格敏感度的本土供應商和跨國公司都創造了機會。

不孕症治療領域的競爭取決於產品的可靠性、整合的臨床工作流程以及以服務主導的部署策略，這些策略能夠加速技術的應用。

輔助生殖技術 (ART) 生態系統中各公司的競爭格局反映了臨床可靠性、產品創新和策略服務合作之間的平衡。領先的儀器製造商和檢查室解決方案供應商透過可靠性、易用性和整合工作流程來降低檢查室變異性，脫穎而出。耗材和培養基供應商則在配方一致性、法規遵循和供應穩定性方面競爭，因為可重複的性能直接影響臨床結果。服務型公司正擴大提供培訓、遠端監控和檢查室品質保證等捆綁式服務，以支援診所實施相關技術並降低其在擴大病例規模過程中面臨的營運風險。

為企業加強臨床夥伴關係、供應鏈韌性、綜合服務和區域市場進入效率所採取的實際策略行動。

產業領導企業應採取一系列重點措施，在確保競爭優勢的同時，維持臨床完整性和病患療效。首先，優先與成熟診所建立合作關係，共同製定治療方案並產生真實世界數據（REW），以支持產品價值提案。使產品開發週期與臨床醫生的需求保持一致，有助於企業縮短產品上市時間，並增強醫療專業人員對新治療方法的信心。其次，投資於供應鏈韌性以及區域製造和分銷系統，以減輕貿易中斷和關稅波動的影響，從而確保獲利能力和服務連續性。

整合臨床、營運和商業性要求，以確定在不斷發展的輔助生殖技術 (ART) 生態系統中永續的競爭優勢。

總之，輔助生殖技術正處於一個轉折點，臨床創新、營運成熟度和市場動態在此交匯融合，造就了差異化的贏家。隨著市場的發展，技術特定需求、週期類型偏好、治療方法、終端使用者能力和產品定位之間的相互作用將決定誰能最終獲益。相關人員，將更有能力在實現穩健規模化的同時，持續取得令人滿意的成果。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：輔助生殖科技市場：依產品分類

  • 消耗品
  • 裝置
  • 培養基和試劑
  • 服務

第9章：輔助生殖科技市場：依科技分類

  • 輸卵管內配子移植
  • 體外受精
    • 新鮮捐贈者
    • 新鮮非捐贈者
    • 冰凍
  • 胞漿內單一精子注射（ICSI）
  • 子宮內人工授精
  • 受精卵輸卵管內移植

第10章：輔助生殖科技市場：依週期類型分類

  • 新鮮捐贈者
  • 新鮮非捐贈者
  • 冰凍

第11章：輔助生殖科技市場：依治療方法分類

  • 冷凍保存
  • 胚胎移植
  • 基因檢測
  • 卵子收集

第12章：輔助生殖技術市場：依最終用戶分類

  • 門診手術中心
  • 不孕症治療診所
  • 醫院

第13章：輔助生殖科技市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：輔助生殖科技市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：輔助生殖科技市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國：輔助生殖技術市場

第17章 中國：輔助生殖技術市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bloom IVF Centre Ltd.
  • Boston IVF, LLC
  • Cook Medical Inc.
  • CReATe Fertility Centre Ltd.
  • Cryoport, Inc.
  • Esco Micro Pte. Ltd.
  • European Sperm Bank A/S
  • Ferring Pharmaceuticals BV
  • FUJIFILM Irvine Scientific, Inc.
  • Genea BIOMEDX Pty Ltd.
  • Hamilton Thorne, Inc.
  • INVO Bioscience, Inc.
  • IVFtech as
  • Kitazato Corporation
  • LENUS Pharma GesmbH
  • Merck KGaA
  • Microm（UK）Ltd.
  • Monash IVF Group Ltd.
  • Ovascience, Inc.
  • Progyny, Inc.
  • Thermo Fisher Scientific Inc.
  • The Cooper Companies, Inc.
  • Vitrolife AB
  • Zita West Fertility Ltd.
Product Code: MRR-436901065A94

The Assisted Reproductive Technology Market was valued at USD 34.76 billion in 2025 and is projected to grow to USD 40.94 billion in 2026, with a CAGR of 18.11%, reaching USD 111.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.76 billion
Estimated Year [2026] USD 40.94 billion
Forecast Year [2032] USD 111.51 billion
CAGR (%) 18.11%

Concise strategic framing of clinical, operational, and commercial dynamics reshaping assisted reproductive technology services and stakeholder priorities

Assisted reproductive technology is evolving at a pace that requires stakeholders to revisit assumptions about clinical practice, commercial models, and patient journeys. Emerging laboratory techniques, expanding provider networks, and shifting patient expectations are converging to reshape care delivery. As a result, leaders across clinical, diagnostic, equipment, and adjacent service segments must synthesize medical, regulatory, and commercial signals to make timely, evidence-based decisions.

This executive summary synthesizes core dynamics affecting practitioners, product developers, payers, and investors. It focuses on clinical technique distribution, treatment pathway nuances, product and service differentiation, and end-user adoption patterns. By framing the discussion around technique, cycle type, treatment modality, end-user, and product lines, the narrative offers a cohesive perspective on how clinical advances and system-level forces are interacting to create new opportunities and operational challenges. The aim is to provide a strategic lens that supports decision-making under uncertainty, while signalling where near-term action can deliver outsized value.

How scientific breakthroughs, operational consolidation, and digital innovations are jointly reshaping clinical pathways and commercial models in assisted reproduction

The landscape of assisted reproductive technology is experiencing transformative shifts driven by scientific innovation, operational consolidation, and patient-centric care models. Advances in genetic testing and embryo selection methods are refining clinical pathways, reducing cycle variability, and increasing the emphasis on pre-procedural diagnostics. Concurrently, laboratory automation and improvements in cryopreservation chemistry are enabling clinics to streamline throughput and enhance reproducibility across treatments.

Operationally, consolidation among fertility providers and increased collaboration between ambulatory surgical centers and hospital systems are creating new referral patterns and scale advantages. Private equity and strategic investors continue to reshape the marketplace, prompting standardization of care protocols and the emergence of centralized laboratory services. In parallel, digital health platforms are simplifying patient onboarding, remote monitoring, and data capture, which is helping clinics improve adherence and clinical outcomes. Regulatory scrutiny and payer engagement are adapting to these changes, emphasizing quality metrics, real-world evidence, and cost-effectiveness, which collectively alter how new technologies are adopted and reimbursed.

Assessment of how recent tariff changes and trade dynamics are reshaping procurement, manufacturing footprints, and cost management strategies across the assisted reproduction supply chain

Tariff policy changes and international trade dynamics are exerting cumulative effects on the supply chain for assisted reproductive technology components and equipment. Import duties can influence the landed cost of specialized laboratory equipment, microscopes, incubators, and cryogenic storage systems, while tariffs on reagents and media affect recurring operational expenditures for clinics and centralized labs. As a consequence, procurement practices are shifting toward diversified sourcing strategies and increased emphasis on vendor partnerships with resilient logistics capabilities.

Manufacturers and service providers are responding by re-evaluating production footprints, increasing localization of critical components, and negotiating supply contracts that incorporate tariff contingencies. Clinics and laboratories are reassessing capital acquisition timelines and exploring flexible financing structures to mitigate near-term cost escalations. In addition, some stakeholders are accelerating investments in domestic manufacturing or regional distribution hubs to reduce exposure to cross-border tariff volatility. These adaptive measures collectively dampen immediate operational disruption but require longer-term alignment between procurement, clinical leadership, and commercial strategy to sustain cost control while preserving quality of care.

Leveraging multidimensional segmentation to prioritize product development, clinical support, and commercial approaches across technique, cycle type, treatment, end user, and product categories

Insightful segmentation-based analysis illuminates how clinical techniques, cycle types, treatment modalities, end-user settings, and product categories each drive distinct commercial imperatives and adoption barriers. Across techniques such as gamete intrafallopian transfer, in vitro fertilization, intracytoplasmic sperm injection, intrauterine insemination, and zygote intrafallopian transfer, practices vary in resource intensity, technician skill requirements, and laboratory infrastructure needs, with in vitro fertilization representing a focal point given its procedural complexity and breadth of clinical pathways that include fresh donor, fresh non-donor, and frozen cycles. Considering cycle type, the distinctions among fresh donor, fresh non-donor, and frozen approaches influence scheduling, cryostorage demand, and patient counseling priorities, prompting clinics to develop differentiated operational playbooks.

When evaluated through the lens of treatment categories such as cryopreservation, embryo transfer, genetic testing, and oocyte retrieval, opportunities for specialization and service bundling become apparent, particularly where genetic testing can be integrated early in the patient journey to inform downstream clinical decisions. End-user environments-spanning ambulatory surgical centers, fertility clinics, and hospitals-present varying capital structures, regulatory oversight, and patient throughput constraints that affect investment cycles for new equipment and consumables. Lastly, product segmentation into consumables, equipment, media and reagents, and services highlights divergent margin profiles and innovation vectors; consumables and media demand frequent replenishment and regulatory compliance, whereas equipment and services represent higher-ticket investments with extended adoption timelines. Taken together, these segmentation dimensions enable stakeholders to prioritize product development, target commercialization strategies, and tailor clinical support models to maximize clinical value and operational efficiency.

How regional regulatory environments, clinical expertise distribution, and patient demand patterns create differentiated opportunities across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are materially shaping clinical practice patterns, investment appetite, and regulatory trajectories in assisted reproductive technologies. In the Americas, a mix of private and public healthcare funding drives competitive clinic networks, strong patient demand, and active venture-backed innovation, with urban centers concentrating specialized laboratory capabilities. Europe, Middle East & Africa displays heterogenous regulatory regimes and reimbursement frameworks that influence market entry and the adoption curve for advanced diagnostics and laboratory automation; cross-border collaboration and medical tourism also affect where specialized services are delivered. Asia-Pacific is characterized by rapid capacity expansion, rising clinical expertise, and varying levels of regulatory maturity, creating opportunities for both domestic suppliers and multinational firms that can adapt to local clinical workflows and price sensitivities.

These regional distinctions have direct implications for supply chain design, commercial partnerships, and clinical training programs. Manufacturers and service providers must navigate distinct certification requirements, import regulations, and payer expectations while developing localized value propositions. Moreover, regional patient preferences and cultural considerations shape demand for cycle types and treatment modalities, which in turn influence how clinics structure care pathways and patient engagement strategies. Effective regional plans therefore combine regulatory foresight, local partnerships, and culturally attuned patient support to accelerate adoption and sustain long-term clinical outcomes.

Competitive dynamics defined by product reliability, integrated clinical workflows, and service-led adoption strategies that accelerate technology acceptance in fertility care

Competitive dynamics among companies operating in the assisted reproductive technology ecosystem reflect a balance between clinical credibility, product innovation, and strategic service partnerships. Leading equipment manufacturers and laboratory solution providers differentiate through reliability, ease of use, and integrated workflows that reduce laboratory variability. Consumable and media suppliers compete on formulation stability, regulatory compliance, and supply continuity, as reproducible performance directly affects clinical outcomes. Service-oriented firms are increasingly bundling training, remote monitoring, and laboratory quality assurance to support adoption and mitigate operational risk for clinics expanding their case volumes.

Strategic collaboration between clinicians and commercial teams continues to be a major driver of product refinement, with early adopters serving as reference sites that validate new approaches. Meanwhile, some companies are scaling through partnerships with ambulatory surgical centers and hospital systems to embed technology into established care pathways. The most effective market participants combine technical excellence with robust post-sale support, clear regulatory positioning, and an ability to demonstrate workflow efficiencies that translate into measurable clinical or economic benefits for provider organizations.

Practical strategic actions for companies to enhance clinical partnership, supply resilience, integrated offerings, and regional go-to-market effectiveness

Industry leaders should pursue a focused set of actions to secure competitive advantage while preserving clinical integrity and patient outcomes. First, prioritize partnerships with high-performing clinics to co-develop protocols and to generate real-world evidence that reinforces product value propositions. By aligning product development cycles with clinician needs, companies can reduce time-to-adoption and increase practitioner confidence in new modalities. Second, invest in supply chain resilience and regional manufacturing or distribution arrangements to mitigate the effects of trade disruptions and tariff shifts, thereby protecting margins and service continuity.

Third, adopt integrated commercial models that combine equipment, consumables, and clinically oriented services such as training and quality management to create bundled offerings that simplify procurement and operational onboarding for end users. Fourth, tailor regional go-to-market strategies that reflect local regulatory, cultural, and payer environments, ensuring that pricing, reimbursement support, and patient communication are aligned with market realities. Finally, commit resources to digital enablement-patient engagement platforms, remote monitoring, and data analytics-to improve adherence, optimize throughput, and generate longitudinal evidence that supports both clinical and economic value claims. Collectively, these actions position organizations to respond nimbly to market shifts and to capitalize on clinical and operational advancements.

The research methodology underpinning these insights combines a structured review of clinical literature, regulatory materials, and publicly available guidance with qualitative interviews of clinicians, laboratory directors, and commercial executives. Evidence synthesis prioritized high-quality clinical studies, consensus statements from professional societies, and documentation of regulatory trends to ensure conclusions reflect current practice patterns and governance expectations. Interview data were used to validate operational assumptions, understand procurement behaviors, and surface emerging product preferences that may not yet be captured in formal publications.

Analytical approaches included comparative assessment across technique, cycle type, treatment, end-user, and product segmentation to reveal differentiation drivers and adoption barriers. Regional analysis incorporated regulatory pathways, reimbursement nuances, and capacity indicators to contextualize commercial implications. Throughout, emphasis was placed on triangulation-aligning quantitative signals from documented sources with qualitative observations from field experts-to produce actionable perspectives while acknowledging areas of ongoing uncertainty and the need for continuous evidence monitoring.

Synthesis of clinical, operational, and commercial imperatives that will determine sustainable competitive advantage in the evolving assisted reproductive technology ecosystem

In conclusion, assisted reproductive technology is at an inflection point where clinical innovation, operational sophistication, and market dynamics converge to create differentiated winners. The interplay between technique-specific demands, cycle type preferences, treatment modalities, end-user capabilities, and product positioning will determine who captures value as the market evolves. Stakeholders that proactively align clinical evidence generation with resilient supply strategies and integrated service models will be best positioned to deliver consistent outcomes while scaling responsibly.

Decision-makers should therefore prioritize partnerships that accelerate real-world validation, invest in regional supply continuity, and adopt commercial approaches that simplify adoption for providers. By focusing on these priorities, organizations can both improve patient care and establish defensible commercial propositions in a sector where clinical credibility and operational excellence are essential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Assisted Reproductive Technology Market, by Product

  • 8.1. Consumables
  • 8.2. Equipment
  • 8.3. Media And Reagents
  • 8.4. Services

9. Assisted Reproductive Technology Market, by Technique

  • 9.1. Gamete Intrafallopian Transfer
  • 9.2. In Vitro Fertilization
    • 9.2.1. Fresh Donor
    • 9.2.2. Fresh Non-Donor
    • 9.2.3. Frozen
  • 9.3. Intracytoplasmic Sperm Injection
  • 9.4. Intrauterine Insemination
  • 9.5. Zygote Intrafallopian Transfer

10. Assisted Reproductive Technology Market, by Cycle Type

  • 10.1. Fresh Donor
  • 10.2. Fresh Non-Donor
  • 10.3. Frozen

11. Assisted Reproductive Technology Market, by Treatment

  • 11.1. Cryopreservation
  • 11.2. Embryo Transfer
  • 11.3. Genetic Testing
  • 11.4. Oocyte Retrieval

12. Assisted Reproductive Technology Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Fertility Clinics
  • 12.3. Hospitals

13. Assisted Reproductive Technology Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Assisted Reproductive Technology Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Assisted Reproductive Technology Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Assisted Reproductive Technology Market

17. China Assisted Reproductive Technology Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bloom IVF Centre Ltd.
  • 18.6. Boston IVF, LLC
  • 18.7. Cook Medical Inc.
  • 18.8. CReATe Fertility Centre Ltd.
  • 18.9. Cryoport, Inc.
  • 18.10. Esco Micro Pte. Ltd.
  • 18.11. European Sperm Bank A/S
  • 18.12. Ferring Pharmaceuticals B.V.
  • 18.13. FUJIFILM Irvine Scientific, Inc.
  • 18.14. Genea BIOMEDX Pty Ltd.
  • 18.15. Hamilton Thorne, Inc.
  • 18.16. INVO Bioscience, Inc.
  • 18.17. IVFtech a.s.
  • 18.18. Kitazato Corporation
  • 18.19. LENUS Pharma GesmbH
  • 18.20. Merck KGaA
  • 18.21. Microm (UK) Ltd.
  • 18.22. Monash IVF Group Ltd.
  • 18.23. Ovascience, Inc.
  • 18.24. Progyny, Inc.
  • 18.25. Thermo Fisher Scientific Inc.
  • 18.26. The Cooper Companies, Inc.
  • 18.27. Vitrolife AB
  • 18.28. Zita West Fertility Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY MEDIA AND REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GAMETE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRACYTOPLASMIC SPERM INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY INTRAUTERINE INSEMINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY ZYGOTE INTRAFALLOPIAN TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FRESH NON-DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FROZEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CRYOPRESERVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY EMBRYO TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY OOCYTE RETRIEVAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY FERTILITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY IN VITRO FERTILIZATION, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY CYCLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ASSISTED REPRODUCTIVE TECHNOLOGY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)